← Leaderboards
Berge A Minassian
University Of Kentucky
$2,734,249
Attributed
$3,493,095
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $773.5K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,493,095 · 2
By mechanism
P01$1,975,403 · 1
U01$1,517,692 · 1
Top collaborators
- Steven J Gray2 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Joan J Guinovart$705,752
- David Stewart Watt$1,694,827
- Craig R Rush$27,535,139
- Mary Kathryn Brewer$103,310
- Pamela E Knapp$12,958,922
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadGene TherapyChildNerve DegenerationGenesGeneticNervous System DisorderEnzymesVectorSymptomsBlood - Brain Barrier AnatomyEpilepsyAntisense Oligonucleotide TherapyAdolescentDependovirusAntisense OligonucleotidesDisease ProgressionCessation Of LifeChemistryBase PairingCytoplasmDendritesCollaborationsAntiepileptic Agents
Grant awards (7)
IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial$744,158
U01 · FY2025 · NS
IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial$773,534
U01 · FY2024 · NS
Genome editing, mRNA suppression and chain termintion as therapy for Lafora Epilepsy$462,095
P01 · FY2020 · NS · contact PI
Genome editing, mRNA suppression and chain termintion as therapy for Lafora Epilepsy$378,140
P01 · FY2019 · NS · contact PI
Genome editing, mRNA suppression and chain termintion as therapy for Lafora Epilepsy$359,094
P01 · FY2018 · NS · contact PI
Genome editing, mRNA suppression and chain termintion as therapy for Lafora Epilepsy$371,053
P01 · FY2017 · NS · contact PI
Genome editing, mRNA suppression and chain termintion as therapy for Lafora Epilepsy$405,021
P01 · FY2016 · NS · contact PI